Inhibition of human immunodeficiency virus type 1 by triciribine involves the accessory protein nef

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 4, 2010, Pages 1512-1519

  Ptak, Roger G ^a,b   Gentry, Brian G ^b   Hartman, Tracy L ^a,c   Watson, Karen M ^a,c   Osterling, M Clayton ^a   Buckheit Jr , Robert W ^a,c   Townsend, Leroy B ^b   Drach, John C ^b  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ImQuest Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; NEF PROTEIN; RNA DIRECTED DNA POLYMERASE; TRICIRIBINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA SEQUENCE; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; POINT MUTATION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIROGENESIS; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; GENES, NEF; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POINT MUTATION; RIBONUCLEOSIDES; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 77950124855     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01443-09     Document Type: Article

References (68)

1. Aiken, C., J. Konner, N. R. Landau, M. E. Lenburg, and D. Trono. 1994. Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864.
2. Aiken, C., and D. Trono. 1995. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69:5048-5056.
3. Aiken, C., L. Krause, Y.-L. Chen, and D. Trono. 1996. Mutational analysis of HIV-1 nef: identification of two mutants that are temperature-sensitive for CD4 downregulation. Virology 217:293-300.
4. Bennett, L. L., Jr., P. W. Allan, and C.-H. Chang. 1983. Phosphorylation of "tricyclic nucleoside" by adenosine kinases from L1210 cells and HEp-2 cells. Biochem. Pharmacol. 32:2601-2602.
5. - mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J. Virol. 69:2058-2067.
6. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retroviruses 7:295-302.
7. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, C. A. Pyle, E. L. White, B. J. Bowdon, J. B. McMahon, M. R. Boyd, and J. P. Bader. 1994. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:43-56.
8. Buckheit, R. M., Jr., J. L. Roberson, C. Lackman-Smith, J. R. Wyatt, T. A. Vickers, and D. J. Ecker. 1994. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 10:1497-1506.
9. Bukrinsky, M., and A. Adzhubei. 1999. Viral protein R of HIV-1. Rev. Med. Virol. 9:39-49.
10. Cloyd, M. W., and B. E. Moore. 1990. Spectrum of biological properties of human immunodeficiency virus (HIV-1) isolates. Virology 174:103-116.
11. Curtain, C. C., M. G. Lowe, C. K. Arunagiri, P. W. Mobley, I. G. Macreadie, and A. A. Azad. 1997. Cytotoxic activity of the amino-terminal region of HIV type 1 Nef protein. AIDS Res. Hum. Retroviruses 13:1213-1220.
12. Demirov, D. G., J. M. Orenstein, and E. O. Freed. 2002. The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J. Virol. 76:105-117.
13. Du, D. L., D. A. Volpe, C. K. Grieshaber, and M. J. Murphy. 1992. In vitro toxicity of 3′-azido-3′-deoxythymidine, carbovir and 2′,3′-didehydro-2′,3′-dideoxythymidine to human and murine haematopoietic progenitor cells. Br. J. Haematol. 80:437-445.
14. Dutartre, H., M. Harris, D. Olive, and Y. Collette. 1998. The human immunodeficiency virus type 1 Nef protein binds the Src-related tyrosine kinase Lck SH2 domain through a novel phophotyrosine independent mechanism. Virology 247:200-211.
15. Engelman, A., and R. Craigie. 1992. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 66:6361-6369.
16. Fackler, O. T., and A. D. Baur. 2002. Live and let die: nef functions beyond HIV replication. Immunity 16:493-497.
17. Feun, L. G., N. Savaraj, G. P. Bodey, K. Lu, B. S. Yap, J. A. Ajani, M. A. Burgess, R. S. Benjamin, E. McKelvey, and I. Krakoff. 1984. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 44:3608-3612.
18. Feun, L. G., J. A. Blessing, R. J. Barrett, and P. Hanjani. 1993. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol. 16:506-508.
19. + T lymphocytes and macrophages. J. Virol. 77:2539-2549.
20. Geleziunas, R., W. Xu, K. Takeda, H. Ichijo, and W. C. Greene. 2001. HIV-1 inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 410:834-838.
21. Geraghty, R. J., K. J. Talbot, M. Callahan, W. Harper, and A. T. Panganiban. 1994. Cell type-dependence for Vpu function. J. Med. Primatol. 23:146-150.
22. Geyer, M., O. T. Fackler, and M. Peterlin. 2001. Structure-function relationship in HIV-1 Nef. EMBO Rep. 2:580-585.
23. Gopalakrishnan, V., J. A. Peliska, and S. J. Benkovic. 1992. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc. Natl. Acad. Sci. U. S. A. 89:10763-10767.
24. Greenway, A. L., D. A. McPhee, K. Allen, R. Johnstone, G. Holloway, J. Mills, A. Azad, S. Sankovich, and P. Lambert. 2002. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J. Virol. 76:2692-2702.
25. Harris, M. 1999. HIV: a new role for nef in the spread of HIV. Curr. Biol. 9:R459-R461.
26. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Petersen-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. (Erratum, 116:629, 2004.)
27. Hodge, D. R., K. J. Dunn, G. K. Pei, M. K. Chakrabarty, G. Heidecker, J. A. Lautenberger, and K. P. Samuel. 1998. Binding of c-Raf1 kinase to a conserved acidic sequence within the carboxyl-terminal region of the HIV-1 Nef protein. J. Biol. Chem. 273:15727-15733.
28. Hoffman, K., F. A. Holmes, G. Fraschini, L. Esparza, D. Frye, M. N. Raber, R. A. Newman, and G. N. Hortobagyi. 1996. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother. Pharmacol. 37:254-258.
29. Hua, J., W. Blair, R. Truant, and B. R. Cullen. 1997. Identification of regions in HIV-1 Nef required for efficient downregulation of cell surface CD4. Virology 231:231-238.
30. Iafrate, A. J., S. Bronson, and J. Skowronski. 1997. Separable functions of Nef disrupt two aspects of T cell receptor machinery: CD4 expression and CD3 signaling. EMBO J. 16:673-684.
31. Kanmogne, G. D., R. C. Kennedy, and P. Grammas. 2001. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res. Hum. Retroviruses 17:45-53.
32. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
33. Kim, D., H. C. Dan, S. Park, L. Yang, Q. Liu, S. Kaneko, J. Ning, L. He, H. Yang, M. Sun, V. Nicosia, and J. Q. Cheng. 2005. AKT/PKB signaling mechanisms in cancer and chemoresistance. Frontiers Biosci. 10:975-987.
34. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated ß-galactosidase gene J. Virol. 66:2232-2239.
35. Klein, R. J. 1975. Isolation of herpes simplex virus clones and drug resistant mutants in microcultures. Arch. Virol. 49:73-80.
36. Konvalinka, J., M. A. Litterst, R. Welker, H. Kottler, F. Rippmann, A. M. Heuser, and H. G. Krausslich. 1995. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J. Virol. 69:7180-7186.
37. Kucera, L. S., N. P. Iyer, S. H. Puckett, R. W. Buckheit, Jr., L. Westbrook, B. R. Toyer, E. L. White, J. M. Germany-Decker, W. M. Shannon, R. C.-S. Chen, M. R. Nassiri, C. Shipman, Jr., L. B. Townsend, and J. C. Drach. 1993. Activity of triciribine and triciribine-5′-monophosphate against human immunodeficiency virus types 1 and 2. AIDS Res. Hum. Retroviruses 9:307-314.
38. Marsh, J. W. 1999. The numerous effector functions of Nef. Arch. Biochem. Biophys. 365:192-198.
39. Mittelman, A., E. S. Casper, T. A. Godwin, C. Cassidy, and C. W. Young. 1983. Phase I study of tricyclic nucleoside phosphate. Cancer Treat. Rep. 67:159-162.
40. Miyazaki, Y., T. Takamatsu, T. Nosaka, S. Fujita, T. E. Martin, and M. Hatanaka. 1995. The cytotoxicity of human immunodeficiency virus type 1 Rev: implications for its interaction with the nucleolar protein B23. Exp. Cell Res. 219:93-101.
41. Neil, S. J., T. Zang, and P. D. Bienias. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
42. + T cells. J. Immunol. 153:5826-5837.
43. Peliska, J. A., S. Balasubramanian, D. P. Giedroc, and S. J. Benkovic. 1994. Recombinant HIV-1 nucleocapsid protein accelerates HIV-1 reverse transcriptase catalyzed DNA strand transfer reactions and modulates RNase activity. Biochemistry 33:13817-13823.
44. Pettit, S. C., J. N. Lindquist, A. H. Kaplan, and R. Swanstrom. 2005. Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology 2:66.
45. Porcari, A. R., K. Z. Borysko, R. G. Ptak, J. M. Breitenbach, L. L. Wotring, J. C. Drach, and L. B. Townsend. 1999. Acyclic sugar analogs of triciribine: lack of antiviral and antiproliferative activity correlate with low intracellular phosphorylation. Nucleosides Nucleotides 18:2475-2497.
46. Porcari, A. R., R. G. Ptak, K. Z. Borysko, J. M. Breitenbach, S. Vittori, L. L. Wotring, J. C. Drach, and L. B. Townsend. 2000. Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation. J. Med. Chem. 43:2438-2448.
47. Powis, G., P. J. Basseches, D. M. Kroschel, R. L. Richardson, M. J. O'Connell, and L. K. Kvols. 1986. Disposition of tricyclic nucleoside-5′-monophosphate in blood and plasma of patients during phase I and II clinical trials. Cancer Treat. Rep. 70:359-362.
48. Ptak, R. G., K. Z. Borysko, A. R. Porcari, J. L. Buthod, L. E. Holland, C. Shipman, Jr., L. B. Townsend, and J. C. Drach. 1998. Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res. Hum. Retroviruses 14:1315-1322.
49. Ptak, R. G., J. G. Jacobson, K. Z. Borysko, L. B. Townsend, and J. C. Drach. 1998. Abstr. 5th Conf. Retroviruses Opportunistic Infect., abstr. 354.
50. Renkema, G. H., and K. Saksela. 2000. Interactions of HIV-1 Nef with cellular signal transducing proteins. Front. Biosci. 5:d268-d283.
51. Roeth, J. F., and K. L. Collins. 2006. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol. Mol. Biol. Rev. 70:548-563.
52. + viruses but not for down-regulation of CD4. EMBO J. 14:484-491.
53. Saksela, K. 1997. HIV-1 Nef and host cell protein kinases. Front. Biosci. 2:d606-d618.
54. Sawai, E. T., A. D. Baur, B. M. Peterlin, J. A. Levy, and C. Cheng-Mayer. 1995. A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J. Biol. Chem. 270:15307-15314.
55. Schilcher, R. B., C. D. Haas, M. K. Samson, J. D. Young, and L. H. Baker. 1986. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5′-phosphate using a weekly intravenous regimen. Cancer Res. 46:3147-3151.
56. Schram, K. H., and L. B. Townsend. 1971. The synthesis of 6-amino-4-methyl-8-(ß-D-ribofuranosyl)-(4-H,8-H)pyrrolo[4,3, 2-d,e]pyrimido[4,5-c]pyridazine, a new tricyclic nucleoside. Tetrahedron Lett. 49:4757-4760.
57. Schubert, U., S. Bour, A. V. Ferrer-Montiel, M. Montal, F. Maldarelli, and K. Strebel. 1996. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 70:809-819.
58. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
59. Steffens, C. M., and T. J. Hope. 2001. Recent advances in the understanding of HIV accessory protein function. AIDS 15:S21-S26.
60. Tachado, S. D., X. Li, K. Swan, N. Patel, and H. Koziel. 2008. Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-α release in alveolar macrophages from asymptomatic HIV-positive persons in vitro. J. Biol. Chem. 283:33191-33198.
61. Tokunaga, K., A. Kojima, T. Kurata, K. Ikuta, H. Akari, A. H. Koyama, M. Kawamura, R. Inubushi, R. Shimano, and A. Adachi. 1998. Enhancement of human immunodeficiency virus type 1 infectivity by Nef is producer cell-dependent. J. Gen. Virol. 79:2447-2453.
62. Vieira, A. 1998. Structural similarity of two T cell signaling regulators suggests a conserved and interactive mechanism of immunosuppression. Mol. Immunol. 35:881-884.
63. Watanabe, H., T. Shiratori, H. Shoji, S. Miyatake, Y. Okazaki, K. Ikuta, T. Sato, and T. Saito. 1997. A novel acyl-CoA thioesterase enhances its enzymatic activity by direct binding with HIV Nef. Biochem. Biophys. Res. Commun. 238:234-239.
64. Wotring, L. L., G. W. Crabtree, N. L. Edwards, J. R. E. Parks, and L. B. Townsend. 1986. Mechanism of activation of triciribine phosphate (TCN-P) as a prodrug form of TCN. Cancer Treat. Rep. 70:491-497.
65. Wotring, L. L., J. L. Roti-Roti, J. L. Hudson, J. E. Passiatore, K. Z. Borysko, R. D. Newcomb, and L. B. Townsend. 1987. Triciribine (TCN), a novel tricyclic adenosine analog with anticancer activity. Nucleosides Nucleotides 6:95-109.
66. Wotring, L. L., L. B. Townsend, L. M. Jones, K. Z. Borysko, D. L. Gildersleeve, and W. B. Parker. 1990. Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res. 50:4891-4899.
67. Xu, X. N., B. Laffert, G. R. Screaton, M. Kraft, D. Wolf, W. Kolanus, J. Mongkolsapay, A. J. McMichael, and A. S. Baur. 1999. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor ζ chain. J. Exp. Med. 189:1489-1496.
68. Yang, L., H. C. Dan, M. Sun, Q. Liu, X. Sun, R. I. Feldman, A. D. Hamilton, M. Polokoff, S. V. Nicosia, M. Herlyn, S. M. Sebti, and J. Q. Cheng. 2004. Akt/Protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64:4394-4399.